Onconic registers Phase 3 trial of JP-1366-based triple therapy for H. Pylori
The study, led by Onconic Therapeutics Inc., plans to enroll 414 participants and begin recruiting on November 1, 2026. It is a multicenter, randomized, double-blind, active-controlled Phase III trial to evaluate the efficacy and safety of JP-1366-based triple therapy in H. Pylori-positive subjects.
Primary source
ClinicalTrials.gov registry record, October 15, 2026
Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects
Read the source: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation